Pharynx Cancer Completed Phase 0 Trials for Bevacizumab (DB00112)

IndicationStatusPhase
DBCOND0031604 (Pharynx Cancer)Completed0
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00140556Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck CancerTreatment